NASDAQ : DTIL
Precision BioSciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.44 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 205.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 194.87M |
| Enterprise Value | 135.42M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 27.60M |
| Shares Outstanding | 27.60M |
| Shares Change (YoY) | +128.47% |
| Shares Change (QoQ) | +4.96% |
| Owned by Insiders (%) | 6.29% |
| Owned by Institutions (%) | 70.29% |
| Float | 25.45M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.33 |
| Forward PS | 74.24 |
| PB Ratio | 4.12 |
| P/TBV Ratio | 4.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.82 |
| Quick Ratio | 12.26 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.55 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -135.15% |
| Return on Assets (ROA) | -19.37% |
| Return on Invested Capital (ROIC) | -33.23% |
| Return on Capital Employed (ROCE) | -30.64% |
| Weighted Average Cost of Capital (WACC) | 10.31% |
| Revenue Per Employee | $672,463 |
| Profits Per Employee | -$787,045 |
| Employee Count | 67 |
| Asset Turnover | 0.38 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -16.25% |
| 50-Day Moving Average | 6.90 |
| 200-Day Moving Average | 6.54 |
| Relative Strength Index (RSI) | 55.82 |
| Average Volume (20 Days) | 224,461 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.36M |
| Short Previous Month | 2.51M |
| Short % of Shares Out | 8.54% |
| Short % of Float | 9.26% |
| Short Ratio (days to cover) | 8.59 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 45.06M |
| Gross Profit | 45.06M |
| Operating Income | -36.40M |
| Pretax Income | -53.62M |
| Net Income | -52.73M |
| EBITDA | -35.15M |
| EBIT | -36.40M |
| Loss Per Share | -$2.59 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 87.55M |
| Total Debt | 28.10M |
| Net Cash | 59.45M |
| Net Cash Per Share | $2.15 |
| Equity (Book Value) | 45.29M |
| Book Value Per Share | 1.71 |
| Working Capital | 84.41M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -51.90M |
| Capital Expenditures | -37,000 |
| Depreciation & Amortization | 1.25M |
| Net Borrowing | n/a |
| Free Cash Flow | -51.94M |
| FCF Per Share | -$1.88 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -80.78% |
| Pretax Margin | -119.00% |
| Profit Margin | -117.04% |
| EBITDA Margin | -78.01% |
| EBIT Margin | -80.78% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -128.47% |
| Shareholder Yield | -128.47% |
| Earnings Yield | -36.68% |
| FCF Yield | -26.65% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $29.40 |
| Price Target Difference | 316.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -15.51% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 14, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.4 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |